Compare BFRG & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFRG | APM |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United Kingdom |
| Employees | 17 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.3M |
| IPO Year | N/A | 2018 |
| Metric | BFRG | APM |
|---|---|---|
| Price | $0.69 | $0.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 280.3K | 255.6K |
| Earning Date | 05-12-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.43 | $0.65 |
| 52 Week High | $2.04 | $4.47 |
| Indicator | BFRG | APM |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 43.86 |
| Support Level | $0.65 | $0.74 |
| Resistance Level | $0.82 | $0.93 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 77.88 | 3.81 |
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.